BrainStorm Announces Presentation of NurOwn® Exosome Preclinical Data at ISCT 2022 San Francisco Meeting; NurOwn-Derived Exosomes Showed More Potent Anti-Inflammatory Effects in Vitro Compared to Naïve Mesenchymal Stem Cell-Derived Exosomes

On May 4, 2022, BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation of a poster titled, "MSC-NTF Derived Small Extracellular Vesicles Display Superior Macrophage Immunomodulation Compared with Vesicles Derived from Naïve MSCs," at the International Society of  Cell & Gene Therapy ISCT 2022 Meeting, being held from May 4-7, 2022 in San Francisco, California. The poster will be presented by Kim Thacker, MD, Senior Vice President, Medical Affairs and Clinical Innovation, BrainStorm Cell Therapeutics.

Login Or Register To Read Full Story